Related Experiment Video
Updated: May 18, 2026
12:45
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
Midline extraperitoneal approach for retroperitoneal lymph node dissection for testicular germ cell tumor
Philip Kim1, Sumeet Syan-Bhanvadia, Hooman Djaladat
1University of Southern California Institute of Urology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033-9178, USA.
Urology
|September 7, 2012
Summary
A new midline extraperitoneal approach for retroperitoneal lymph node dissection (EP-RPLND) in testicular cancer patients offers significant benefits. This technique reduces operative time, blood loss, and hospital stay while improving outcomes.
Area of Science:
- Urology
- Surgical Oncology
- Oncology
Background:
- Retroperitoneal lymph node dissection (RPLND) for testicular germ cell tumors is complex and morbid.
- A novel midline extraperitoneal (EP) approach was investigated to reduce morbidity.
Purpose of the Study:
- To evaluate the safety and efficacy of a midline extraperitoneal approach for RPLND.
- To compare outcomes of EP-RPLND with the traditional transperitoneal approach.
Main Methods:
- A retrospective review of 12 patients undergoing EP-RPLND by a single surgeon.
- Comparison of operative time, blood loss, lymph node yield, bowel function, and length of stay with a matched transperitoneal-RPLND cohort.
Main Results:
- EP-RPLND demonstrated shorter operative times (292 vs. 337 minutes) and less blood loss (305 vs. 575 mL).
- Higher lymph node yield (44 vs. 27 nodes) was observed in the EP group.
- Earlier return of bowel function (1.7 vs. 2.9 days) and shorter hospital stay (3.3 vs. 5.3 days) were significant benefits of EP-RPLND.
Conclusions:
- The midline extraperitoneal approach for RPLND is safe and effective for testicular cancer.
- EP-RPLND offers advantages including reduced operative time, blood loss, and faster recovery.
- This approach is suitable for both primary and postchemotherapy RPLND.
